Table 2.
Treatments
| Primary immunodeficiencies (n = 20) | Idiopathic and post infectious (n = 39) | Other etiologies (n = 39) | All (n = 98) | P value | |
|---|---|---|---|---|---|
| Azithromycin | 9 (45%) | 21 (53.9%) | 21 (53.9%) | 51 (52%) | 0.78 |
| Omalizumab | 0* | 4 (10.3%) | 7 (17.9%)* | 11 (11.2%) | 0.044 |
| Immunoglobulin substitution | 17 (85%)£ | 1 (2.6%)£ | 7 (17.9%)£ | 25 (25.5%) | < 0.001 |
| Inhaled treatments | 10 (50%) | 26 (66.7%) | 27 (69.2%) | 63 (70.4%) | 0.32 |
| Corticosteroids | 6 (30%) | 17 (43.6%) | 19 (48.7%) | 42 (42.9%) | 0.39 |
| Long-acting β-agonist | 9 (45%) | 26 (66.7%) | 25 (64.1%) | 60 (61.2%) | 0.24 |
| Anticholinergic | 4 (20%) | 7 (17.9%) | 9 (23.1%) | 20 (20.4%) | 0.85 |
| Triple association | 2 (10%) | 4 (10.3%) | 4 (10.3%) | 10 (10.2%) | 0.99 |
| Statin use | 1 (5%) | 5 (12.8%) | 10 (25.6%) | 16 (16.3%) | 0.95 |